National Retina Research Network Invites Dr. Shami to Discuss Current Study Protocols
The U.S.-based, federally funded DRCR Retina Network recently invited Texas Retina’s Michel J. Shami, MD, to provide investigators with updates on three of the network’s current studies: Protocol AF: A randomized trial
read more
New Clinical Trials Available at Texas Retina
Medical researchers continue to make significant advances in the diagnosis and treatment of many retina conditions, discovering new sight-saving treatments for diseases that once robbed patients of their vision. That is why
read more
Texas Retina First in the US to Randomize a Patient in the i-SIGHT2 Bioelectric Therapy for Dry AMD Clinical Trial
The i-SIGHT2 pivotal clinical trial is evaluating the investigational i-Lumen AMD System for patients with intermediate to advanced dry age-related macular degeneration (AMD), and on July 1, 2026, Texas Retina’s Patrick D.
read more
Dr. Abbey Participates in ReachMD CME on Sustained-Delivery TKIs for Wet AMD
Texas Retina’s Ashkan M. Abbey, MD, recently participated in a continuing medical education (CME) program through ReachMD, titled, “Redefining Durability in nAMD: The Science and Strategy of Sustained-Delivery TKIs.” During the program,
read more
Dr. Abbey Doses First Patient in Phase 1b/2a LOTUS-2 Clinical Trial of Novel Multivalent Fusion Antibody EB-105 for Diabetic Macular Edema
On October 28, 2025, Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, dosed the first patient in the Phase 1b/2a LOTUS-2 clinical trial of novel multivalent fusion antibody (EB-105) for diabetic
read more
Dr. Ashkan Abbey Presented at the American Academy of Ophthalmology Annual Meeting
Texas Retina’s Ashkan M. Abbey, MD, presented, taught and served as a panelist at AAO 2025, the American Academy of Ophthalmology’s annual meeting held in Orlando, Florida, October 18-20, 2025. Highlights of
read more Dr. Abbey Spoke About the VERONA Diabetic Macular Edema Clinical Trial at The Retina Society’s Annual Meeting
On behalf of the VERONA study investigators, Texas Retina’s Ashkan M. Abbey, MD, delivered a presentation titled “VERONA: End-of-Study Results from a Phase 2 Trial of EYP-1901 (vorolanib intravitreal insert) versus Aflibercept
read more
Texas Retina Research Team Members Attended Ollin Study Meeting in Maui
This past weekend, seven members of Texas Retina’s research team were invited to attend the Ollin Study Coordinators meeting in Maui, Hawaii. Ollin is a Phase Ib study of two different formulations
read more
Texas Retina Clinical Research Coordinator Rachel McCullough Participates in Panel Discussion for LUGANO and LUCIA Clinical Trials
At a recent meeting in San Antonio, Texas Retina Clinical Research Coordinator Rachel McCullough participated in a panel discussion with study coordinators for EyePoint Pharmaceuticals’ pivotal Phase III LUGANO and LUCIA clinical
read more
Texas Retina’s Melissa Alva Recognized as a Top Study Coordinator in Clinical Research for 2024
InFocus, an international provider of ophthalmology clinical research and development services, recently named Texas Retina Senior Clinical Research Coordinator Melissa Alva as a “Top Study Coordinator in Retina Clinical Research for 2024,”
read more